The Glioma International CaseControl Study: A Report From the Genetic Epidemiology of Glioma International Consortium, Am J Epidemiol. 15 janv, vol.183, issue.2, pp.85-91, 2016. ,
Primary brain tumour epidemiology in Georgia: first-year results of a population-based study, J Neurooncol. avr, vol.112, issue.2, pp.241-247, 2013. ,
,
, Neurochirurgie. févr, vol.58, issue.1, pp.4-13, 2012.
Genome-wide association study of glioma and meta-analysis, Hum Genet. déc, vol.131, issue.12, pp.1877-88, 2012. ,
Epidemiology of brain tumors, Neurol Clin, vol.25, issue.4, pp.867-90, 2007. ,
Long-term use of cellular phones and brain tumours: increased risk associated with use for > or =10 years, Occup Environ Med. sept, vol.64, issue.9, pp.626-658, 2007. ,
Evaluation of the potential of mobile phone specific electromagnetic fields (UMTS) to produce micronuclei in human glioblastoma cell lines, Toxicol In Vitro. avr, vol.40, pp.264-71, 2017. ,
Conventional MRI evaluation of gliomas, Br J Radiol. déc, vol.84, issue.2, pp.107-111, 2011. ,
High-grade glioma management and response assessment-recent advances and current challenges, Curr Oncol. août, vol.23, issue.4, pp.383-391, 2016. ,
Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas, Ann Neurol. sept, vol.60, issue.3, pp.380-383, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00163977
Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Neuroradiology, vol.49, pp.795-803, 2007. ,
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy, Br J Cancer. 7 juin, vol.104, issue.12, pp.1854-61, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01469461
Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas, J Neurooncol. mai, vol.107, issue.3, pp.527-562, 2012. ,
PET-FDG of untreated and treated cerebral gliomas, J Nucl Med. mars, vol.29, issue.3, pp.421-424, 1988. ,
Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor, Eur J Nucl Med Mol Imaging. avr, vol.44, issue.4, pp.611-620, 2017. ,
Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation, Semin Nucl Med. mars, vol.45, issue.2, pp.136-50, 2015. ,
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial, Neuro-oncology. août, vol.17, issue.8, pp.1148-56, 2015. ,
MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice, AJNR Am J Neuroradiol. mai, vol.33, issue.5, pp.803-820, 2012. ,
Advantages of high b-value diffusionweighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment, Eur J Radiol, vol.81, issue.10, pp.2805-2815, 2012. ,
Intravoxel incoherent motion diffusion-weighted imaging analysis of diffusion and microperfusion in grading gliomas and comparison with arterial spin labeling for evaluation of tumor perfusion, J Magn Reson Imaging. sept, vol.44, issue.3, pp.620-652, 2016. ,
Dynamic Contrast-Enhanced Perfusion MRI and Diffusion-Weighted Imaging in Grading of Gliomas, J Neuroimaging, vol.25, issue.5, pp.792-800, 2015. ,
The role of biopsy in the management of patients with presumed diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline, J Neurooncol. déc, vol.125, issue.3, pp.481-501, 2015. ,
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, vol.131, issue.6, pp.803-823, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
A simplified classification of the gliomas, Proc Staff Meet Mayo Clin. 2 févr ,
The new WHO classification of brain tumours, Brain Pathol. juill ,
WHO Classification of Tumours of the Central Nervous System, Acta Neuropathologica. 12 juill, vol.114, issue.2, pp.97-109, 2007. ,
A classification of tumors of the glioma groupo on a histogenetic basis with a correlation study of prognosis (1926), J.B Lippincott Co. 28. Zülch KJ. Types histologiques des tumeurs du système nerveux central. Genève: Organisation mondiale de la santé, 1979. ,
Analysis of the IDH1 codon 132 mutation in brain tumors, Acta Neuropathol. déc, vol.116, issue.6, pp.597-602, 2008. ,
Classification histologique et moléculaire des gliomes, Revue Neurologique. juin, vol.164, issue.6-7, pp.505-520, 2008. ,
Primary and secondary glioblastomas: from concept to clinical diagnosis, Neuro-oncology ,
Genetic pathways to primary and secondary glioblastoma, Am J Pathol. mai, vol.170, issue.5, pp.1445-53, 2007. ,
34. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective, J Neuropathol Exp Neurol. sept, vol.65, issue.9, pp.297-304, 2006. ,
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading, Brain Pathol. sept, vol.24, issue.5, pp.429-464, 2014. ,
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?, Lancet Oncol. janv, vol.12, issue.1, pp.83-91, 2011. ,
IDH1 and IDH2 Mutations in Gliomas. Current Neurology and Neuroscience Reports, 2013. ,
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas, Am J Pathol. avr, vol.174, issue.4, pp.1149-53, 2009. ,
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha, Science. 10 avr, vol.324, issue.5924, pp.261-266, 2009. ,
IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas, J Neurooncol. juill, vol.108, issue.3, pp.403-413, 2012. ,
An integrated genomic analysis of human glioblastoma multiforme, Science. 26 sept, vol.321, issue.5897, pp.1807-1819, 2008. ,
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma, Acta Neuropathol. avr, vol.119, issue.4, pp.487-94, 2010. ,
Mutant metabolic enzymes are at the origin of gliomas, Cancer Res. 15 déc, vol.69, issue.24, pp.9157-9166, 2009. ,
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas, Neuro-oncology. août, vol.11, issue.4, pp.341-348, 2009. ,
Expression of mutated isocitrate dehydrogenase-1 ,
, in gliomas is associated with p53 and EGFR expression, Folia Neuropathol, vol.49, issue.2, pp.88-93, 2011.
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas, J Clin Oncol. 1 sept, vol.27, issue.25, pp.4150-4154, 2009. ,
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas, Acta Neuropathol, vol.118, issue.4, pp.469-74, 2009. ,
, Cancer Genome Atlas Research Network
, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas, N Engl J Med. 25 juin, vol.372, issue.26, pp.2481-98, 2015.
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma, Cancer Res, vol.66, issue.20, pp.9852-61, 2006. ,
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH, 51. van den Bent MJ, vol.32, pp.1276-84, 2003. ,
Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival, Brain Pathol. avr, vol.14, issue.2, pp.121-151, 2004. ,
Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas, Clin Cancer Res. 1 mars, vol.13, issue.5, pp.1429-1466, 2007. ,
Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin, Nat Struct Mol Biol. 12 juin, vol.18, issue.7, pp.777-82, 2011. ,
Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres, Proc Natl Acad Sci, vol.107, issue.32, pp.14075-80, 2010. ,
The chromatin remodeller ATRX: a repeat offender in human disease, Trends Biochem Sci. sept, vol.38, issue.9, pp.461-467, 2013. ,
Altered telomeres in tumors with ATRX and DAXX mutations, Science. 22 juill, vol.333, issue.6041, p.425, 2011. ,
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations, Acta Neuropathol, vol.124, issue.5, pp.615-640, 2012. ,
ATRX and the replication of structured DNA, Curr Opin Genet Dev. juin, vol.23, issue.3, pp.289-94, 2013. ,
,
Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas, Brain Tumor Pathol. avr, vol.33, issue.2, pp.107-123, 2016. ,
Epidermal growth factor receptor in glioblastoma, Oncology Letters. juill, vol.14, issue.1, pp.512-518, 2017. ,
The somatic genomic landscape of glioblastoma, Cell, vol.155, issue.2, pp.462-77, 2013. ,
Genetic pathways to glioblastoma: a population-based study, Cancer Res, vol.64, pp.6892-6901, 2004. ,
EGFR and EGFRvIII in glioblastoma: partners in crime, Cancer Cell, vol.24, issue.4, pp.403-407, 2013. ,
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity, Proc Natl Acad Sci, vol.91, issue.16, pp.7727-7758, 1994. ,
Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas, Proc Natl Acad Sci, vol.87, issue.21, pp.8602-8608, 1990. ,
A common mutant epidermal growth factor ,
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme, Cancer Res, vol.63, issue.20, pp.6962-70, 2003. ,
Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance, Radiother Oncol. juin, vol.83, issue.3, pp.333-342, 2007. ,
The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations, Brain Pathol. janv, vol.21, issue.1, pp.74-87, 2011. ,
Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis, Int J Clin Exp Med, vol.8, issue.4, pp.6553-62, 2015. ,
, Correlation between O6-methylguanine
, DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide, J Neurooncol. avr, vol.102, issue.2, pp.311-317, 2011.
, , pp.1-19
, co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution, Mod Pathol. juill, vol.26, issue.7, pp.922-931, 2013.
Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas, Oncology Letters. juill, vol.6, issue.1, pp.130-134, 2013. ,
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors, Acta Neuropathol. janv, vol.331, issue.6021, pp.133-179, 2011. ,
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin, J Clin Oncol. 1 déc, vol.29, issue.34, pp.4482-90, 2011. ,
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma, Neuro-oncology, vol.16, issue.11, pp.1478-83, 2014. ,
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol. mai, vol.10, issue.5, pp.459-66, 2009. ,
Temozolomide: mechanisms of action, repair and resistance, Curr Mol Pharmacol. janv, vol.5, issue.1, pp.102-116, 2012. ,
Toward precision medicine in glioblastoma: the promise and the challenges, Neuro-Oncology. août, vol.17, issue.8, pp.1051-63, 2015. ,
Treatment options for recurrent glioblastoma: pitfalls and future trends, Expert Rev Anticancer Ther. mai, vol.9, issue.5, pp.613-622, 2009. ,
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. sept, vol.25, issue.3, pp.93-101, 2014. ,
Radiation therapy of glioblastoma, Cancer Treat Res, vol.163, pp.49-73, 2015. ,
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis, Medicine (Baltimore). mai, vol.94, issue.20, pp.1032-1040, 2012. ,
The effect of re-operation on survival in patients with recurrent glioblastoma, Anticancer Res. mars, vol.35, issue.3, pp.1743-1751, 2015. ,
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma, J Clin Oncol, vol.28, issue.30, pp.4601-4609, 2010. ,
Novel strategies in glioblastoma surgery aim at safe, supra-maximum resection in conjunction with local therapies, Chin J Cancer. janv, vol.33, issue.1, pp.8-15, 2014. ,
Convection-enhanced delivery of macromolecules in the brain, Proc Natl Acad Sci USA. 15 mars, vol.91, issue.6, pp.2076-80, 1994. ,
Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies, J Neurosurg. janv, vol.126, issue.1, pp.191-200, 2017. ,
Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers, J Control Release. 10 avr, vol.159, issue.1, pp.14-26, 2012. ,
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model, J Neurooncol. févr, vol.111, issue.3, pp.229-265, 2013. ,
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neurooncology, vol.5, issue.2, pp.79-88, 2003. ,
Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review, Turk Neurosurg, vol.24, issue.5, pp.639-684, 2014. ,
The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis, Drug Des Devel Ther, vol.9, pp.3341-3349, 2015. ,
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A SingleInstitutional Experience, World Neurosurg. mai, vol.113, pp.508-522, 2018. ,
Hallmarks of glioblastoma: a systematic review ,
AKT/GSK3? Signaling in Glioblastoma, Neurochem Res. mars, vol.42, issue.3, pp.918-942, 2017. ,
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma, Eur J Cancer. mars, vol.51, issue.4, pp.522-554, 2015. ,
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma, Neuro-oncology. juill, vol.16, issue.7, pp.984-90, 2014. ,
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients, J Neurooncol. janv, vol.126, issue.1, pp.185-92, 2016. ,
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme, Neuro-oncology. avr, vol.15, issue.4, pp.490-496, 2013. ,
, , vol.0211
, study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients, Int J Radiat Oncol Biol Phys. 1 avr, vol.85, issue.5, pp.1206-1217, 2013.
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074, Int J Radiat Oncol Biol Phys. 1 juin, vol.80, issue.2, pp.347-53, 2011. ,
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma, Neuro-oncology. mars, vol.17, issue.3, pp.430-439, 2015. ,
A phase I/II trial of GW572016 ,
, (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation, Cancer Chemother Pharmacol. janv, vol.65, issue.2, pp.353-61, 2010.
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study, J Neurooncol. sept, vol.134, issue.2, pp.357-62, 2017. ,
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms, Mol Med Rep. juill, vol.6, issue.1, pp.88-92, 2012. ,
Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients, Clin Cancer Res. 15 août, vol.21, issue.16, pp.3610-3618, 2015. ,
Advances in immunotherapy for the treatment of glioblastoma, J Neurooncol, vol.131, issue.1, pp.1-9, 2017. ,
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study, Neuro-oncology. juin, vol.17, issue.6, pp.854-61, 2015. ,
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial, Lancet Oncol, vol.18, issue.10, pp.1373-85, 2017. ,
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival, Oncoimmunology. avr, vol.5, issue.4, p.1119354, 2016. ,
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma, Br J Cancer. 15 déc, vol.101, issue.12, pp.1995-2004, 2009. ,
Phase 2 trial of dasatinib in targetselected patients with recurrent glioblastoma (RTOG 0627), Neuro-oncology. juill, vol.17, issue.7, pp.992-1000, 2015. ,
A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma, CNS Oncol, vol.5, issue.2, pp.59-67, 2016. ,
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-? tyrosine kinase inhibitor, in patients with recurrent glioblastoma, Neuro-oncology, vol.01, issue.4, pp.567-75, 2017. ,
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature, J Neurosurg Sci. 28 sept, 2016. ,
Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study, Target Oncol. déc, vol.9, issue.4, pp.321-330, 2014. ,
Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme, Anticancer Res. avr, vol.33, issue.4, pp.1657-60, 2013. ,
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02, Neuro-oncology. déc, vol.14, issue.12, pp.1511-1519, 2012. ,
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082), Clin Cancer Res, vol.22, pp.4797-806, 2016. ,
Rapamycin inhibits the growth of glioblastoma, Brain Res. 7 févr, vol.1495, pp.37-51, 2013. ,
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma, J Neurooncol. janv, vol.96, issue.2, pp.219-249, 2010. ,
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K, Neuro-oncology. sept, vol.17, issue.9, pp.1261-1270, 2015. ,
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells, Neuro-oncology. janv, vol.16, issue.1, pp.29-37, 2014. ,
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines, Neuroscience. 27 mars, vol.346, pp.298-308, 2017. ,
, BKM-120 (Buparlisib): A Phosphatidyl
Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats, Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. Sci Rep. 5 févr, vol.6, pp.57-66, 2016. ,
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma, Neuro-oncology. juin, vol.12, issue.6, pp.559-69, 2010. ,
Phase II study of PX-866 in recurrent glioblastoma, Neuro-oncology. sept, vol.17, issue.9, pp.1270-1274, 2015. ,
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma, Neuro-oncology. sept, vol.17, issue.9, pp.1275-83, 2015. ,
A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression, J Neurooncol. avr, vol.107, issue.2, pp.343-352, 2012. ,
Temozolomide and sorafenib as programmed cell death inducers of human glioma cells, Pharmacol Rep. août, vol.69, issue.4, pp.779-87, 2017. ,
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study, Anticancer Res. août, vol.33, issue.8, pp.3487-94, 2013. ,
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial, Clin Cancer Res. 1 sept, vol.19, issue.17, pp.4816-4839, 2013. ,
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme, Cancer. 1 août, vol.116, issue.15, pp.3663-3672, 2010. ,
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylationdependent inhibition of Ras signaling, Biochem Biophys Res Commun, vol.29, issue.3, pp.293-301, 2017. ,
Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme, Neurol Med Chir (Tokyo), vol.53, issue.11, pp.755-63, 2013. ,
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, J Clin Oncol, vol.25, issue.30, pp.4722-4731, 2007. ,
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, vol.27, issue.28, pp.4733-4773, 2009. ,
Bevacizumab and daily temozolomide for recurrent glioblastoma, Cancer. 1 mars, vol.118, issue.5, pp.1302-1314, 2012. ,
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma, J Neurooncol. mars, vol.107, issue.1, pp.155-64, 2012. ,
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, The Lancet Oncology. août, vol.15, issue.9, pp.943-53, 2014. ,
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial, Eur J Cancer. juill, vol.51, issue.10, pp.1321-1351, 2015. ,
Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme, Oncologist. févr, vol.130, issue.3, pp.107-115, 2015. ,
Bevacizumab plus RadiotherapyTemozolomide for Newly Diagnosed Glioblastoma, New England Journal of Medicine. 20 févr, vol.370, issue.8, pp.709-731, 2014. ,
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma, J Neurooncol. mars, vol.122, issue.1, pp.135-178, 2015. ,
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma, New England Journal of Medicine. 20 févr, vol.370, issue.8, pp.699-708, 2014. ,
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial, J Clin Oncol, vol.10, issue.14, pp.1611-1620, 2016. ,
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial, J Neurooncol. mai, vol.127, issue.3, pp.569-79, 2016. ,
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02), Neuro-oncology. août, vol.12, issue.8, pp.855-61, 2010. ,
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme, J Neurooncol. janv, vol.111, issue.2, pp.205-217, 2013. ,
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, J Clin Oncol. 10 juin, vol.28, issue.17, pp.2817-2840, 2010. ,
,
, Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma, PLoS ONE, vol.11, issue.5, p.156369, 2016.
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma, J Cancer Res Clin Oncol. juill, vol.142, issue.7, pp.1581-1590, 2016. ,
Dovitinib enhances temozolomide efficacy in glioblastoma cells, Mol Oncol. août, vol.11, issue.8, pp.1078-98, 2017. ,
Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses, J Clin Oncol. 20 janv, vol.35, issue.3, pp.343-51, 2017. ,
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma, Neuro-oncology. avr, vol.13, issue.4, pp.437-483, 2011. ,
High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More? Clinical Cancer Research, vol.17, pp.6109-6120, 2011. ,
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma, Neuro-oncology. juill, vol.17, issue.7, pp.1007-1022, 2015. ,
An open-label phase Ib doseescalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer, Clin Cancer Res. 1 déc, vol.20, issue.23, pp.5918-5944, 2014. ,
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma, J Clin Oncol. 1 juin, vol.28, issue.16, pp.2712-2720, 2010. ,
A safety run-in and randomized phase 2 ,
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, Lancet Oncol. sept, vol.15, issue.10, pp.1100-1108, 2014. ,
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study, Neuro-oncology. mai, vol.17, issue.5, pp.708-725, 2015. ,
Experimental approaches for the treatment of malignant gliomas ,
, Pharmacol Ther, vol.128, issue.1, pp.1-36, 2010.
Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes, Acta Neuropathol. févr, vol.127, issue.2, pp.203-222, 2014. ,
Molecular and cellular heterogeneity: the hallmark of glioblastoma, Neurosurg Focus. déc, vol.37, issue.6, p.11, 2014. ,
Heterogeneity maintenance in glioblastoma: a social network ,
, Cancer Res. 15 juin, vol.71, issue.12, pp.4055-60, 2011.
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell. mars, vol.9, issue.3, pp.157-73, 2006. ,
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell. 19 janv, vol.17, issue.1, pp.98-110, 2010. ,
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment, Cancer Cell. juill, vol.32, issue.1, pp.42-56, 2017. ,
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype, JCI Insight, vol.1, issue.2, 2016. ,
Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma, Cancer Cell. 11 août, vol.26, issue.2, pp.288-300, 2014. ,
The definition of primary and secondary glioblastoma, Clin Cancer Res. 15 févr, vol.19, issue.4, pp.764-72, 2013. ,
Applicable advances in the molecular pathology of glioblastoma, Brain Tumor Pathol. juill, vol.32, issue.3, pp.153-62, 2015. ,
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma, Ann Oncol. 1 juill, vol.28, issue.7, pp.1448-56, 2017. ,
Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas, Neuro-oncology, vol.01, issue.4, pp.546-57, 2017. ,
From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity, Oncotarget. 20 mai, vol.6, issue.14, pp.12094-109, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01117090
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics, Proc Natl Acad Sci, vol.110, issue.10, pp.4009-4023, 2013. ,
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science. 20 juin, vol.344, issue.6190, pp.1396-401, 2014. ,
Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone, Neuro-oncology, vol.17, issue.10, pp.1322-1354, 2015. ,
Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion, Front Oncol, vol.7, p.120, 2017. ,
Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin, Br J Cancer. 24 juill, vol.107, issue.3, pp.462-470, 2012. ,
MRI-localized biopsies reveal subtypespecific differences in molecular and cellular composition at the margins of glioblastoma, Proc Natl Acad Sci, vol.111, issue.34, pp.12550-12555, 2014. ,
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence, Front Oncol, vol.5, p.251, 2015. ,
Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone, Cancer Res. 1 janv, vol.75, issue.1, p.35262, 2012. ,
Spatiotemporal Evolution of the Primary Glioblastoma Genome, Cancer Cell. 14 sept, vol.28, issue.3, pp.318-346, 2015. ,
Spatiotemporal genomic architecture informs precision oncology in glioblastoma, Nat Genet. avr, vol.49, issue.4, pp.594-603, 2017. ,
Clonal evolution of glioblastoma under therapy, Nat Genet, vol.48, issue.7, pp.768-76, 2016. ,
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma, Neurosurgery. déc, vol.75, issue.6, pp.9-10, 2014. ,
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity, Proc Natl Acad Sci, vol.112, issue.3, pp.851-857, 2015. ,
The Temporal Order of Genetic and Pathway Alterations in Tumorigenesis, Toland AE, éditeur. PLoS ONE, vol.6, issue.11, p.27136, 2011. ,
Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel), janv, vol.27, issue.1, pp.226-265, 2014. ,
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution, Genome Res. mars, vol.25, issue.3, pp.316-343, 2015. ,
Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications. Frontiers in Oncology, Oncogene. 24 mars, vol.5, issue.12, pp.1504-1520, 2016. ,
Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity, Cancer Cell. 9 sept, vol.24, issue.3, p.172791, 2013. ,
Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity, Cancer Res. 1 avr, vol.72, issue.7, pp.1614-1634, 2012. ,
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J Clin Oncol. 1 sept, vol.21, issue.2, pp.4189-99, 2004. ,
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response, Proc Natl Acad Sci, vol.109, issue.8, pp.3041-3047, 2012. ,
Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions, PLoS ONE, vol.9, issue.12, p.115018, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01101651
Functional Subclone Profiling for Prediction of ,
, Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma, Clin Cancer Res. 15 janv, vol.23, issue.2, pp.562-74, 2017.
Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med. 19 févr, vol.6, issue.224, pp.224-248, 2014. ,
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Nat Cell Biol. déc, vol.10, issue.12, pp.1470-1476, 2008. ,
Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay, Cancer Res. 15 avr, vol.74, issue.8, pp.2152-2161, 2014. ,
Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms, J Cell Mol Med, vol.17, issue.10, pp.1218-1253, 2013. ,
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro, Glia. sept, vol.39, issue.3, pp.193-206, 2002. ,
Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma, J Clin Neurosci. août, vol.22, issue.8, pp.1219-1245, 2015. ,
Presence of pluripotent CD133+ cells correlates with malignancy of gliomas, Mol Cell Neurosci. janv, vol.43, issue.1, pp.51-60, 2010. ,
Stemness Marker Detection in the Periphery of Glioblastoma and Ability of Glioblastoma to Generate Glioma Stem Cells: Clinical Correlations, World Neurosurg. sept, vol.105, pp.895-905, 2017. ,
Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells, Proc Natl Acad Sci, vol.109, issue.44, pp.2998-3007, 2012. ,
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model, Cancer Cell. 6 janv, vol.15, issue.1, pp.45-56, 2009. ,
Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance, Stem Cells Int, p.6809105, 2016. ,
Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt-signaling and a fingerprint associated with clinical outcome, Exp Cell Res. 15 août, vol.319, issue.14, pp.2230-2273, 2013. ,
WNT signaling pathway and stem cell signaling network, Clin Cancer Res. 15 juill, vol.13, issue.14, pp.4042-4047, 2007. ,
Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway, Oncogenesis. 31 mars, vol.3, p.96, 2014. ,
LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program, Oncotarget. juill, vol.4, issue.7, pp.1050-64, 2013. ,
Epidermal growth factor receptor and ,
convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis, Cancer Cell. avr, vol.1, issue.3, pp.269-77, 2002. ,
Establishment of human iPSC-based models for the study and targeting of glioma initiating cells, Nat Commun. 22 févr, vol.7, p.10743, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01477820
Cancer stem-like cells can be induced through dedifferentiation under hypoxic conditions in glioma, hepatoma and lung cancer, Cell Death Discov, vol.3, p.16105, 2017. ,
Core pathway mutations induce dedifferentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide, Neuro-oncology, vol.18, issue.7, pp.962-73, 2016. ,
Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice, Science, vol.338, issue.6110, pp.1080-1084, 2012. ,
Hypoxia enhances stemness of cancer stem cells in glioblastoma: an in vitro study ,
, Int J Med Sci, vol.10, issue.4, pp.399-407, 2013.
Plasticity in Glioma Stem Cell Phenotype and Its Therapeutic Implication, Neurol Med Chir (Tokyo). 15 févr, vol.58, issue.2, pp.61-70, 2018. ,
Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance, Cell Death & Disease. nov, vol.5, issue.11, pp.1543-1543, 2014. ,
New aspects of glioblastoma multiforme revealed by similarities between neural and glioblastoma stem cells, Cell Biol Toxicol. 31 janv, 2018. ,
Neural Stem Cells, and Brain Tumors, Cold Spring Harbor Symposia on Quantitative Biology. 1 janv, vol.73, issue.0, pp.367-75, 2008. ,
Aberrant Notch signaling in glioblastoma stem cells contributes to tumor recurrence and invasion, Mol Med Rep. août, vol.14, issue.2, pp.1263-1271, 2016. ,
Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells, Oncotarget [Internet], vol.12, issue.2017 ,
Notch: a membrane-bound transcription factor, J Cell Sci. 15 mars, vol.115, pp.1095-1102, 2002. ,
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma, Oncotarget. 5 juill, vol.7, issue.27, pp.41251-64, 2016. ,
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo, Cancer Res. 15 sept, vol.71, issue.18, pp.6073-83, 2011. ,
Combined EGFRand notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro, Cancer Cell International, vol.16, issue.1 ,
Notch-1 regulates transcription of the epidermal growth factor receptor through p53, Carcinogenesis. mai, vol.29, issue.5, pp.918-943, 2008. ,
Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma, Brain Tumor Pathol. juill, vol.32, issue.3, pp.176-83, 2015. ,
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo, Nat Neurosci. janv, vol.6, issue.1, pp.21-28, 2003. ,
Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway, J Pathol. sept, vol.234, issue.1, pp.11-22, 2014. ,
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence, Expert Rev Neurother, vol.15, issue.7, pp.741-52, 2015. ,
Smoothened is a poor prognosis factor and a potential therapeutic target in glioma, Sci Rep. 14 févr, vol.7, p.42630, 2017. ,
Potential role of Shh-Gli1-BMI1 signaling pathway nexus in glioma chemoresistance, Tumour Biol, vol.37, issue.11, pp.15107-15121, 2016. ,
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment, J Exp Clin Cancer Res, vol.28, issue.1, p.184, 2016. ,
Wnt signaling and stem cell control, Cell Res. mai, vol.18, issue.5, pp.523-530, 2008. ,
Wnt signaling regulates symmetry of division of neural stem cells in the adult brain and in response to injury, Stem Cells. mars, vol.29, issue.3, pp.528-566, 2011. ,
WNT signaling in glioblastoma and therapeutic opportunities, Lab Invest. févr, vol.96, issue.2, pp.137-50, 2016. ,
Targeting WNT Signaling for Multifaceted Glioblastoma Therapy, Front Cell Neurosci, vol.11, p.318, 2017. ,
Lgr4 promotes glioma cell proliferation through activation of Wnt signaling ,
, Asian Pac J Cancer Prev, vol.14, issue.8, pp.4907-4918, 2013.
The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor, Genes (Basel). 17 févr, vol.9, issue.2, 2018. ,
Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma, Oncotarget, vol.8, issue.47, pp.82217-82247, 2017. ,
Astrocyte Elevated Gene-1 Regulates ?-Catenin Signaling to Maintain Glioma Stem-like Stemness and Self-Renewal, Mol Cancer Res, vol.15, issue.2, pp.225-258, 2017. ,
Wnt3a mediated activation of Wnt/?-catenin signaling promotes tumor progression in glioblastoma, Mol Cell Neurosci. mai, vol.54, pp.44-57, 2013. ,
Glioblastoma cancer stem cells--from concept to clinical application, Cancer Lett. 10 sept, vol.338, issue.1, pp.32-40, 2013. ,
Snail regulates BMP and TGF? pathways to control the differentiation status of glioma-initiating cells, Oncogene. mai, vol.37, pp.2515-2546, 2018. ,
The Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells, Front Oncol, vol.7, p.143, 2017. ,
Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells. Ulasov I, éditeur, Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy. Frontiers in Pharmacology, vol.7, p.24807, 2011. ,
Identification of a cancer stem cell in human brain tumors, Cancer Res. 15 sept, vol.63, issue.18, pp.5821-5829, 2003. ,
Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies, Expert Rev Neurother. mai, vol.13, issue.5, pp.545-55, 2013. ,
ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells, Sci Rep, vol.26, p.25956, 2016. ,
, Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival, Stem Cells International, vol.2018, pp.1-19, 2018.
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma, Adv Exp Med Biol, vol.853, pp.111-149, 2015. ,
A perivascular niche for brain tumor stem cells, Cancer Cell. janv, vol.11, issue.1, pp.69-82, 2007. ,
Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells, Cancer Res. 15 sept, vol.71, issue.18, pp.6061-72, 2011. ,
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment, Front Cell Neurosci, vol.8, p.144, 2014. ,
Osteopontin mediates survival, proliferation and migration of neural stem cells through the chemokine receptor CXCR4, Stem Cell Res Ther. 22 mai, vol.6, p.99, 2015. ,
Integrin alpha 6 regulates glioblastoma stem cells, Cell Stem Cell. 7 mai, vol.6, issue.5, pp.421-453, 2010. ,
Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets, Stem Cells International, vol.2016, pp.1-20, 2016. ,
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas, Cancer Res. 1 avr, vol.68, issue.7, pp.2241-2250, 2008. ,
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells, Cell Stem Cell. 5 févr, vol.6, issue.2, pp.141-52, 2010. ,
Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor, Stem Cells. mai, vol.30, issue.5, pp.845-53, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01541440
CD133+ and Nestin+ Glioma Stem-Like Cells Reside Around CD31+ Arterioles in Niches that Express SDF-1?, CXCR4, Osteopontin and Cathepsin K, J Histochem Cytochem, vol.63, issue.7, pp.481-93, 2015. ,
Glioblastoma stem-like cells give rise to tumour endothelium, Nature. 9 déc, vol.468, issue.7325, pp.829-862, 2010. ,
Tumor and endothelial cell hybrids participate in glioblastoma vasculature, Biomed Res Int, p.827327, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01308223
The role of pericytes in blood-vessel formation and maintenance, Neuro-Oncology ,
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth, Cell. 28 mars, vol.153, issue.1, pp.139-52, 2013. ,
Endogenous Brain Pericytes Are Widely Activated and Contribute to Mouse Glioma Microvasculature. Castro MG, éditeur, PLOS ONE. 13 avr, vol.10, issue.4, p.123553, 2015. ,
, Human Glioblastoma-Derived Mesenchymal Stem Cell
, Pericytes Transition and Angiogenic Capacity in Glioblastoma Microenvironment, Cell Physiol Biochem, vol.46, issue.1, pp.279-90, 2018.
Human glioma stem-like cells induce malignant transformation of bone marrow mesenchymal stem cells by activating TERT expression, Oncotarget, vol.8, issue.61, pp.104418-104447, 2017. ,
Revealing the glioma cancer stem cell interactome, one niche at a time, J Pathol. mars, vol.244, issue.3, pp.260-264, 2018. ,
Vascular regulation of glioma stem-like cells: a balancing act, Curr Opin Neurobiol. déc, vol.47, pp.8-15, 2017. ,
Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution ,
, Oncogene. 16 avr, vol.28, issue.15, pp.1807-1818, 2009.
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption, Neoplasia. août, vol.2, issue.4, pp.306-320, 2000. ,
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma, Proc Natl Acad Sci, vol.108, issue.9, pp.3749-54, 2011. ,
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells, Cell Oncol (Dordr). juin, vol.41, issue.3, pp.319-347, 2018. ,
Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway, J Biol Chem. 5 mars, vol.274, issue.10, pp.6519-6544, 1999. ,
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 4 févr, vol.29, pp.625-659, 2010. ,
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis, Neuro-oncology. avr, vol.7, issue.2, pp.134-53, 2005. ,
The hypoxic microenvironment maintains ,
Metabolic regulation of glioma stem-like cells in the tumor micro-environment, Cancer Lett, vol.01, pp.174-81, 2017. ,
Clinical and prognostic significance of HIF-1? in glioma patients: a meta-analysis, Int J Clin Exp Med, vol.8, issue.12, pp.22073-83, 2015. ,
HIF-1? is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway, Cell Death Differ. févr, vol.19, issue.2, pp.284-94, 2012. ,
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma, Stem Cells. mai, vol.28, issue.5, pp.851-62, 2010. ,
Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha, Oncogene, vol.12, issue.45, pp.3949-59, 2009. ,
HIF1? regulates single differentiated glioma cell dedifferentiation to stem-like cell phenotypes with high tumorigenic potential under hypoxia, Oncotarget. 25 avr, vol.8, issue.17, pp.28074-92, 2017. ,
Hypoxia and hypoxia-inducible factors: master regulators of metastasis, Clin Cancer Res. 15 déc, vol.16, issue.24, pp.5928-5963, 2010. ,
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha, Brain. avr, vol.133, pp.983-95, 2010. ,
HIF-2? mediates a marked increase in migration and stemness characteristics in a subset of glioma cells under hypoxia by activating an Oct-4/Sox-2-Mena (INV) axis, Int J Biochem Cell Biol. mai, vol.74, pp.60-71, 2016. ,
HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth, Genes Dev. 1 mars, vol.20, issue.5, pp.557-70, 2006. ,
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells, Cancer Cell. 2 juin, vol.15, issue.6, pp.501-514, 2009. ,
, Anticancer Agents Med Chem, vol.16, issue.1, pp.59-74, 2016.
Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model, Lab Invest. janv, vol.92, issue.1, pp.151-62, 2012. ,
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-oncology, vol.12, pp.1113-1138, 2010. ,
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway, Mol Cancer Ther. janv, vol.9, issue.1, pp.67-78, 2010. ,
, Cancer Stem Cell
, Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion, Stem Cells, vol.34, issue.8, pp.2026-2065, 2016.
Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression, Cell Stem Cell, p.6 ,
CD133 is essential for glioblastoma stem cell maintenance, Stem Cells. mai, vol.31, issue.5, pp.857-69, 2013. ,
Cancer stem cells in nervous system tumors, Oncogene. 20 sept, vol.23, issue.43, pp.7267-73, 2004. ,
CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells ,
, 18 juin, vol.10, issue.6, p.130519, 2015.
Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression, Cell Biol Int. janv, vol.36, issue.1, pp.29-38, 2012. ,
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma, Cancer Cell. 13 avr, vol.17, issue.4, pp.362-75, 2010. ,
, CD133(+) and CD133(-) glioblastoma
Transcriptional profiles of CD133+ and CD133-glioblastoma-derived cancer stem cell lines suggest different cells of origin, Cancer Res. 1 mars, vol.70, issue.5, pp.2030-2070, 2010. ,
Targeted therapy against cancer stem cells, Oncol Lett. juill, vol.10, issue.1, pp.27-33, 2015. ,
Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3, Proc Natl Acad Sci, vol.110, issue.21, pp.8644-8653, 2013. ,
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme, Oncotarget. 20 mars, vol.6, issue.8, pp.6267-80, 2015. ,
Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells, Genom Data. 1 sept, vol.5, pp.333-339, 2015. ,
PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype, Oncotarget. 29 août, vol.8, issue.35, pp.59282-300, 2017. ,
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells, Oncotarget. 4 avr, vol.8, issue.14, pp.22325-22368, 2017. ,
Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome, Sci Rep. 9 févr, vol.6, p.21557, 2016. ,
Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth, Cell Stem Cell. 6 mars, vol.14, issue.3, pp.357-69, 2014. ,
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma, J Pathol. déc, vol.243, issue.4, pp.468-80, 2017. ,
Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level, Cell Rep, vol.03, issue.1, pp.23-31, 2017. ,
,
, Regulate Glioma Invasion through the TGF-? Pathway, Cell Rep, vol.26, issue.4, pp.950-66, 2016.
The Anti-Warburg Effect Elicited by the cAMP-PGC1? Pathway Drives Differentiation of Glioblastoma Cells into, Astrocytes. Cell Rep, vol.10, issue.2, pp.468-81, 2017. ,
Energy metabolism in glioblastoma stem cells: PPAR? a metabolic adaptor to intratumoral microenvironment, Oncotarget. 12 déc, vol.8, issue.65, pp.108430-50, 2017. ,
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake, Nature Neuroscience, vol.16, issue.10, pp.1373-82, 2013. ,
A restricted cell population propagates glioblastoma growth after chemotherapy, Nature. août, vol.488, issue.7412, pp.522-528, 2012. ,
Targeting glioma stemlike cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B, Mol Oncol. mars, vol.12, issue.3, pp.406-426, 2018. ,
The Impact of Hedgehog Signaling Pathway on DNA Repair Mechanisms in Human Cancer, Cancers (Basel). 21 juill, vol.7, issue.3, pp.1333-1381, 2015. ,
The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells, Ultrasonics. janv, vol.53, issue.1, pp.232-240, 2013. ,
Effect of siRNA-Livin on drug resistance to chemotherapy in glioma U251 cells and CD133+ stem cells. Experimental and Therapeutic Medicine, vol.10, pp.1317-1340, 2015. ,
Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells, Brain Res. 8 juin, vol.1336, pp.103-114, 2010. ,
Downregulation of ABCG2 protein inhibits migration and invasion in U251 glioma stem cells, Neuroreport. 28 mai, vol.25, issue.8, pp.625-657, 2014. ,
Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy, Stem Cells International, vol.2016, pp.1-16, 2016. ,
Stem cell marker CD133 affects clinical outcome in glioma patients, Clin Cancer Res. 1 janv, vol.14, issue.1, pp.123-132, 2008. ,
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature. 7 déc, vol.444, issue.7120, pp.756-60, 2006. ,
Radiation-induced G2/M arrest rarely occurred in glioblastoma stemlike cells, Int J Radiat Biol. avr, vol.94, issue.4, pp.394-402, 2018. ,
, but not Chk2, is responsible for G2/M phase arrest induced by diallyl disulfide in human gastric cancer BGC823 cells, vol.68, pp.61-70, 2014.
Targeting Notch to overcome radiation resistance, Oncotarget. 16 févr, vol.7, issue.7, pp.7610-7638, 2016. ,
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy, Cell Death Differ. juill, vol.21, issue.7, pp.1119-1150, 2014. ,
Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model, Mol Cancer Ther, vol.15, issue.12, pp.3064-76, 2016. ,
Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment, Oncotarget. 8 déc, vol.8, issue.64, pp.108064-78, 2017. ,
Molecular mechanisms underlying tumor dormancy, Cancer Lett. 28 août, vol.294, issue.2, pp.139-185, 2010. ,
Chemoquiescence for ideal cancer treatment and prevention: where are we now?, J Cancer Prev. juin, vol.19, issue.2, pp.89-86, 2014. ,
Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro, BMC Cancer, vol.8, p.304, 2008. ,
Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties, PLoS ONE, vol.10, issue.6, p.127517, 2015. ,
Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/?-catenin/Tcf signaling pathway in human glioblastoma cells, Neurochem Res, vol.38, issue.11, pp.2313-2335, 2013. ,
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma, Neuro-oncology. févr, vol.17, issue.2, pp.266-73, 2015. ,
GSK3beta regulates differentiation and growth arrest in glioblastoma, PLoS ONE, vol.4, issue.10, p.7443, 2009. ,
Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence, Cell Death Dis. 22 mai, vol.5, p.1246, 2014. ,
RYK promotes the stemness of glioblastoma cells via the WNT/ ?-catenin pathway, Oncotarget. 21 févr, vol.8, issue.8, pp.13476-87, 2017. ,
Patient-derived glioblastoma stem cells respond differentially to targeted therapies, Oncotarget. 27 déc, vol.7, issue.52, pp.86406-86425, 2016. ,
Notch signaling, gamma-secretase inhibitors, and cancer therapy, Cancer Res. 1 mars, vol.67, issue.5, pp.1879-82, 2007. ,
A High Notch Pathway Activation Predicts Response to ? ,
, Secretase Inhibitors in Proneural Subtype of Glioma Tumor-Initiating Cells: Targeting Proneural GBM with Notch Inhibition, vol.32, pp.301-313, 2014.
Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate, Stem Cells. juin, vol.28, issue.6, pp.1019-1048, 2010. ,
Strong therapeutic potential of ?-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells, J Drug Target. juill, vol.121, issue.2, pp.523-554, 2015. ,
Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells, Stem Cell Reports, vol.12, issue.6, pp.1948-60, 2017. ,
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma, J Neurooncol, vol.130, issue.3, pp.571-580, 2016. ,
FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2, PLoS ONE, vol.10, issue.10, p.137703, 2015. ,
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors, Cancers (Basel). 15 févr, vol.8, issue.2, 2016. ,
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells, vol.25, pp.2524-2557, 2007. ,
Evaluation of cytotoxic properties of a cyclopamine glucuronide prodrug in rat glioblastoma cells and tumors, J Mol Neurosci. janv, vol.55, issue.1, pp.51-61, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01328060
Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation, Oncotarget. 27 juin, vol.8, issue.26, pp.42495-509, 2017. ,
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy, Aging, vol.9, issue.4, pp.1233-1280, 2017. ,
Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells, Biomaterials. mars, vol.35, issue.9, pp.2859-67, 2014. ,
A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation, Biochim Biophys Acta, vol.1861, issue.9, pp.2282-92, 2017. ,
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells, Cancer Cell. janv, vol.13, issue.1, pp.69-80, 2008. ,
, Reorganizes Chromatin
, Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells, Cell Stem Cell. 3 août, vol.21, issue.2, pp.209-224, 2017.
Intratumoral Heterogeneity of the Epigenome, Cancer Cell. 11 avr, vol.29, issue.4, pp.440-51, 2016. ,
Combined inhibition of AKT/mTOR and MDM2 ,
, enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells, Scientific Reports
, Disponible sur, vol.5, 2015.
Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome, Oncotarget [Internet, issue.9, 2018. ,
, Disponible sur, p.9
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells, Neuro-oncology. févr, vol.15, issue.2, pp.198-207, 2013. ,
Epidermal growth factor receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance, Oncotarget. 22 sept, vol.8, issue.42, pp.72494-512, 2017. ,
Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases, Socovich AM, Naba A. The cancer matrisome: From comprehensive characterization to biomarker discovery, vol.15, pp.1905-1922, 2017. ,
, Semin Cell Dev Biol. 12 juill, 2018.
Bioinformatics analysis of gene expression profiles to identify causal genes in luminal B2 breast cancer, Oncol Lett. déc, vol.14, issue.6, pp.7880-7888, 2017. ,
An extracellular matrix-related prognostic and predictive indicator for earlystage non-small cell lung cancer, Nat Commun, vol.8, issue.1, p.1734, 2017. ,
Inside the Cell: Integrins as New Governors of Nuclear Alterations? Cancers (Basel). 6 juill, vol.9, 2017. ,
Sensing and modulation of invadopodia across a wide range of rigidities, Biophys J. 2 févr, vol.100, issue.3, pp.573-82, 2011. ,
Every step of the way: integrins in cancer progression and metastasis, Nat Rev Cancer. 12 juill, 2018. ,
Hypoxia Selectively Enhances Integrin ?5?1 Receptor Expression in Breast Cancer to Promote Metastasis, Mol Cancer Res. juin, vol.15, issue.6, pp.723-757, 2017. ,
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials, Lancet. 28 avr, vol.379, issue.9826, pp.1591-601, 2012. ,
Platelet Integrins in Tumor Metastasis: Do They Represent a Therapeutic Target? Cancers (Basel). 28 sept, vol.9, 2017. ,
A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment, Blood, vol.120, issue.14, pp.2889-98, 2012. ,
Platelet integrin ?6?1 controls lung metastasis through direct binding to cancer cell-derived ADAM9, JCI Insight, vol.08, issue.14, p.215, 2007. ,
The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy, Perspect Medicin Chem. 10 avr, vol.2, pp.57-73, 2008. ,
Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators, Cancers (Basel). 5 juill, vol.9, issue.7, 2017. ,
A systematic survey of conformational states in ?1 and ?4 integrins using negative-stain electron microscopy, J Cell Sci. 22 mai, vol.131, issue.10, 2018. ,
Relating conformation to function in integrin ?5?1 ,
, Proc Natl Acad Sci, vol.113, issue.27, pp.3872-3881, 2016.
Integrins as therapeutic targets: lessons and opportunities, Nat Rev Drug Discov, vol.9, issue.10, pp.804-824, 2010. ,
Conformational equilibria and intrinsic affinities define integrin activation, EMBO J, vol.01, issue.5, pp.629-674, 2017. ,
Exploring the Role of RGDRecognizing Integrins in Cancer. Cancers (Basel). 4 sept, vol.9, 2017. ,
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation, Anticancer Agents Med Chem. déc, vol.10, issue.10, pp.753-68, 2010. ,
Integrins in cancer: biological implications and therapeutic opportunities, Nat Rev Cancer. janv, vol.10, issue.1, pp.9-22, 2010. ,
E-cadherin-integrin crosstalk in cancer invasion and metastasis, J Cell Sci. 15 janv, vol.126, issue.2, pp.393-401, 2013. ,
Talins and kindlins: partners in integrin-mediated adhesion, Nat Rev Mol Cell Biol. août, vol.14, issue.8, pp.503-520, 2013. ,
Defining the phospho-adhesome through the phosphoproteomic analysis of integrin signalling, Nat Commun. 13 févr, vol.6, p.6265, 2015. ,
Src family kinases in tumor progression and metastasis, Cancer Metastasis Rev. déc, vol.22, issue.4, pp.337-58, 2003. ,
Integrin-mediated signalling through the MAP-kinase pathway, IET Syst Biol. janv, vol.2, issue.1, pp.8-15, 2008. ,
Definition of a consensus integrin adhesome and its dynamics during adhesion complex assembly and disassembly, Nat Cell Biol. déc, vol.17, issue.12, pp.1577-87, 2015. ,
Dynamic regulation of the structure and functions of integrin adhesions, Dev Cell. 11 mars, vol.24, issue.5, pp.447-58, 2013. ,
Kindlin-2 (Mig-2): a co-activator of beta3 integrins, J Cell Biol. 5 mai, vol.181, issue.3, pp.439-485, 2008. ,
Integrin diversity brings specificity in mechanotransduction, Biol Cell. mars, vol.110, issue.3, pp.49-64, 2018. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02058751
Kindlin-2 cooperates with talin to activate integrins and induces cell spreading by directly binding paxillin, Elife. 27 janv, vol.5, p.10130, 2016. ,
Substrate engagement of integrins ?5?1 and ?v?3 is necessary, but not sufficient, for high directional persistence in migration on fibronectin, Sci Rep. 18 mars, vol.6, p.23258, 2016. ,
Appreciating force and shape-the rise of mechanotransduction in cell biology, Nat Rev Mol Cell Biol, vol.15, issue.12, pp.825-858, 2014. ,
Integrin-mediated mechanotransduction, The Journal of Cell Biology, vol.215, issue.4, pp.445-56, 2016. ,
Targeting the integrin interactome in human disease, Current Opinion in Cell Biology. déc, vol.55, pp.17-23, 2018. ,
Hydrogel micropillars with integrin selective peptidomimetic functionalized nanopatterned tops: a new tool for the measurement of cell traction forces transmitted through ?v?3-or ?5?1-integrins, Adv Mater Weinheim, vol.25, issue.41, pp.5869-74, 2013. ,
Mechanical regulation of a molecular clutch defines force transmission and transduction in response to matrix rigidity, Nat Cell Biol, vol.18, issue.5, pp.540-548, 2016. ,
Mechanosensitive components of integrin adhesions: Role of vinculin, Exp Cell Res, vol.10, issue.1, pp.21-28, 2016. ,
Integrins as therapeutic targets, Trends Pharmacol Sci. juill, vol.33, issue.7, pp.405-417, 2012. ,
?v?3 and ?5?1 integrin-specific ligands: From tumor angiogenesis inhibitors to vascularization promoters in regenerative medicine?, Biotechnology Advances. janv, vol.36, issue.1, pp.208-235, 2018. ,
The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets, Proc Natl Acad Sci USA. déc, vol.82, issue.23, pp.8057-61, 1985. ,
Role of abciximab in the treatment of coronary artery disease, Expert Opin Biol Ther. sept, vol.6, issue.9, pp.935-977, 2006. ,
Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting, Curr Pharm Des, vol.12, issue.22, pp.2723-2770, 2006. ,
Integrin-based therapeutics: biological basis, clinical use and new drugs, Nat Rev Drug Discov. mars, vol.15, issue.3, pp.173-83, 2016. ,
Integrins: bidirectional, allosteric signaling machines, Cell. 20 sept, vol.110, issue.6, pp.673-87, 2002. ,
?1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer, Front Pharmacol, vol.6, p.279, 2015. ,
Ligand-independent activation of c-Met by fibronectin and ?(5)?(1)-integrin regulates ovarian cancer invasion and metastasis, Oncogene. 31 mars, vol.30, issue.13, pp.1566-76, 2011. ,
Integrin ?v?3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells, The International Journal of Biochemistry & Cell Biology. janv, vol.40, issue.12, pp.2746-61, 2008. ,
Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis, Cell. 11 août, vol.126, issue.3, pp.489-502, 2006. ,
Insulin-like growth factor (IGF) signaling requires ?v?3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation, J Biol Chem. 1 févr, vol.288, issue.5, pp.3059-69, 2013. ,
Integrin ?3?1-CD151 complex regulates dimerization of ErbB2 via RhoA, Oncogene. 22 mai, vol.33, issue.21, pp.2779-89, 2014. ,
?1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells, Oncogene. 29 sept, vol.30, issue.39, pp.4087-96, 2011. ,
Integrin ?6?4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF), J Biol Chem, vol.290, issue.45, pp.27228-27266, 2015. ,
?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib, Breast Cancer Res. 31 août, vol.13, issue.4, p.84, 2011. ,
Integrins in the Spotlight of Cancer, Int J Mol Sci. 6 déc, vol.17, issue.12, 2016. ,
Cadherin-17 interacts with ?2?1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis ,
, Oncogene. 27 mars, vol.33, issue.13, pp.1658-69, 2014.
Integrin ?4?1 controls G9a activity that regulates epigenetic changes and nuclear properties required for lymphocyte migration, Nucleic Acids Res. 20 avr, vol.44, issue.7, pp.3031-3075, 2016. ,
alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/calmodulin-dependent protein kinase IV, J Cell Biochem. 15 août, vol.95, issue.6, pp.1214-1237, 2005. ,
Integrin signaling in cancer cell survival and chemoresistance, Chemother Res Pract, p.283181, 2012. ,
Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax, Leukemia. févr, vol.13, issue.2, pp.266-74, 1999. ,
Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation, Mol Cell. 18 janv, vol.29, issue.1, pp.9-22, 2008. ,
MMP-9 silencing regulates hTERT expression via ?1 integrin-mediated FAK signaling and induces senescence in glioma xenograft cells, Cell Signal. déc, vol.23, issue.12, pp.2065-75, 2011. ,
Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis, J Cell Biol, vol.143, issue.2, pp.547-60, 1998. ,
A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells, Int J Oncol. janv ,
Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression, Nat Rev Cancer. sept, vol.14, issue.9, pp.632-673, 2014. ,
The ZNF304-integrin axis protects against anoikis in cancer, Nat Commun. 17 juin, vol.6, p.7351, 2015. ,
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition, JCI Insight. 7 juill, vol.1, issue.10, 2016. ,
Integrin endosomal signalling suppresses anoikis, Nat Cell Biol, vol.17, issue.11, pp.1412-1433, 2015. ,
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness, J Mol Cell Biol. août, vol.4, issue.4, pp.207-227, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00771201
Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer, Cancer Res, vol.69, issue.22, pp.8620-8628, 2009. ,
Integrin ?5?1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma, Cancer Res. 15 juill, vol.72, issue.14, pp.3463-70, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00740873
Integrin ?5?1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma, Cell Death Differ. avr, vol.23, issue.4, pp.640-53, 2016. ,
?1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma, Cancer Res. 15 mai, vol.73, issue.10, pp.4398-405, 2008. ,
??Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy, J Clin Invest. avr, vol.122, issue.4, pp.1529-1569, 2012. ,
Integrins in angiogenesis and lymphangiogenesis, Nat Rev Cancer. août, vol.8, issue.8, pp.604-621, 2008. ,
Integrin (alpha 6 beta 4) regulation of eIF-4E ,
, activity and VEGF translation: a survival mechanism for carcinoma cells, J Cell Biol. 8 juill, vol.158, issue.1, pp.165-74, 2002.
Definition of two angiogenic pathways by distinct alpha v integrins, Science. 1 déc, vol.270, issue.5241, pp.1500-1502, 1995. ,
Gln-362 of angiopoietin-2 mediates migration of tumor and endothelial cells through association with ?5?1 integrin, J Biol Chem, vol.289, issue.45, pp.31330-31370, 2014. ,
Dual role of pericyte ?6?1-integrin in tumour blood vessels, J Cell Sci. 1 mai, vol.130, issue.9, pp.1583-95, 2017. ,
Integrin control of the transforming growth factor-? pathway in glioblastoma, Brain. févr, vol.136, issue.2, pp.564-76, 2013. ,
Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased epithelial to mesenchymal transition and prometastatic properties, Oncotarget. 8 déc, vol.6, issue.39, pp.41884-901, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01280454
Expression/activation of ?5?1 integrin is linked to the ?-catenin signaling pathway to drive migration in glioma cells, Oncotarget. 20 sept, vol.7, issue.38, pp.62194-207, 2016. ,
Tumour exosome integrins determine organotropic metastasis, Nature, vol.527, issue.7578, pp.329-364, 2015. ,
Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver, Cancer Sci. mai, vol.99, issue.5, pp.879-87, 2008. ,
Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade, Carcinogenesis. févr, vol.23, issue.2, pp.237-281, 2002. ,
Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells, Proc Natl Acad Sci USA. 5 août, vol.100, issue.16, pp.9482-9489, 2003. ,
The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity, Int J Cancer. 1 août, vol.87, issue.3, pp.336-378, 2000. ,
Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway, Cancer Res. 15 janv, vol.66, issue.2, pp.775-83, 2006. ,
?1-integrin: a potential therapeutic target in the battle against cancer recurrence, Clin Cancer Res. 1 déc, vol.17, issue.23, pp.7219-7242, 2011. ,
Regulated splicing of the ?6 integrin cytoplasmic domain determines the fate of breast cancer stem cells, Cell Rep. 8 mai, vol.7, issue.3, pp.747-61, 2014. ,
Validation of stem cell markers in clinical prostate cancer: ?6-integrin is predictive for non-aggressive disease, Prostate. mai, vol.74, issue.5, pp.488-96, 2014. ,
CD49f-positive cell population efficiently enriches colon cancer-initiating cells, Int J Oncol. août, vol.43, issue.2, pp.425-455, 2013. ,
Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma, Oncol Rep. janv, vol.31, issue.1, pp.262-72, 2014. ,
A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal, Cancer Cell. 8 juill, vol.24, issue.1, pp.59-74, 2013. ,
Integrin ?v?3 drives slug activation and stemness in the pregnant and neoplastic mammary gland, Dev Cell. 11 août, vol.30, issue.3, pp.295-308, 2014. ,
The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis, Cancer Res, vol.68, pp.7711-7718, 2008. ,
Integrin ?7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma, Nature Communications. 7 déc, vol.7, p.13568, 2016. ,
Glioblastoma stem cells exploit the ?v?8 integrin-TGF?1 signaling axis to drive tumor initiation and progression, Stem Cell Investig, vol.23, issue.47, pp.6568-80, 2017. ,
Integrin ?7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma, Cell Stem Cell, vol.06, issue.1, pp.35-50, 2017. ,
Integrin ?3 is overexpressed in glioma stem-like cells and promotes invasion, Br J Cancer. 25 juin, vol.108, issue.12, pp.2516-2540, 2013. ,
Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review, Cancers (Basel). 8 juill, vol.9, issue.7, 2017. ,
Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer, Mol Cancer. 17 juin, vol.9, p.152, 2010. ,
Integrin ?5 triggers the metastatic potential in renal cell carcinoma, Oncotarget. 8 déc, vol.8, issue.64, pp.107530-107572, 2017. ,
Increased expression of ?5?1-integrin is a prognostic marker for patients with gastric cancer, Clinical and Translational Oncology. juill, vol.16, issue.7, pp.668-74, 2014. ,
Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin, Cancer Res. 1 juill, vol.70, issue.13, pp.5238-5286, 2010. ,
Integrin ?5?1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors, Cancers (Basel). 15 janv, vol.5, issue.1, pp.27-47, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00783158
Interaction between integrin alpha(5) and fibronectin is required for metastasis of B16F10 melanoma cells, Biochem Biophys Res Commun. 12 août, vol.333, issue.4, pp.1269-75, 2005. ,
alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer, Am J Respir Cell Mol Biol. déc, vol.43, issue.6, pp.684-91, 2010. ,
Survivin promotion of melanoma metastasis requires upregulation of ?5 integrin, Carcinogenesis. sept, vol.34, issue.9, pp.2137-2181, 2013. ,
Predictive role of galectin-1 and integrin ?5?1 in cisplatinbased neoadjuvant chemotherapy of bulky squamous cervical cancer, Biosci Rep, vol.37, issue.5, 2017. ,
MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α, Oncotarget, vol.5, issue.10, 2016. ,
Role of ?(5)?(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells, Transl Oncol, vol.4, issue.5, pp.282-92, 2011. ,
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes, Cell Reports. juill, vol.20, issue.3, pp.572-85, 2017. ,
Steroid receptor coactivator-1 upregulates integrin ?? expression to promote breast cancer cell adhesion and migration, Cancer Res. 1 mars, vol.71, issue.5, pp.1742-51, 2011. ,
Bone Metastasis in Renal Cell Carcinoma is Preprogrammed in the Primary Tumor and Caused by AKT and Integrin ?5 Signaling, J Urol. août, vol.194, issue.2, pp.539-585, 2015. ,
CD44-mediated activation of ?5?1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and fibronectinenriched matrices, Oncotarget, vol.6, issue.34, pp.36762-73, 2015. ,
AKR1B10 promotes breast cancer metastasis through integrin ?5/?-catenin mediated FAK/Src/Rac1 signaling pathway, Oncotarget. 12 juill, vol.7, issue.28, pp.43779-91, 2016. ,
Integrin ?5 promotes tumor progression and is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma, Hum Pathol. févr, vol.48, pp.69-75, 2016. ,
Proteolytic fragments of fibronectin function as matrikines driving the chemotactic affinity of prostate cancer cells to human bone marrow mesenchymal stromal cells via the ?5?1 integrin, Cell Adhesion & Migration. 4 juill, vol.11, issue.4, pp.305-320, 2017. ,
Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells, Proc Natl Acad Sci USA. 1 août, vol.92, issue.16, pp.7411-7416, 1995. ,
Integrin agonists as adjuvants in chemotherapy for melanoma, Clin Cancer Res, vol.14, pp.6193-6200, 2008. ,
CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo, Int J Cancer. 20 juin, vol.110, issue.3, pp.326-361, 2004. ,
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors, Clin Cancer Res. 1 avr, vol.13, issue.7, pp.2128-2163, 2007. ,
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human ?(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer, Invest New Drugs. août, vol.29, issue.4, pp.674-683, 2011. ,
A randomised, phase II study of intetumumab, an anti-?v-integrin mAb, alone and with dacarbazine in stage IV melanoma, Br J Cancer. 26 juill, vol.105, issue.3, pp.346-52, 2011. ,
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human ?? integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer ,
, Ann Oncol. févr, vol.24, issue.2, pp.329-365, 2013.
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or -dacarbazine in patients with stage IV metastatic melanoma, Cancer. 15 mars, vol.116, issue.6, pp.1526-1560, 2010. ,
,
, Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer, Clin Cancer Res. 1 juill, vol.22, issue.13, pp.3192-200, 2016.
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial, Ann Oncol. janv, vol.26, issue.1, pp.132-172, 2015. ,
Cilengitide targeting of alpha(v)beta(3) ,
, integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts, Cancer Res. 1 août, vol.62, issue.15, pp.4263-72, 2002.
Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models, Int J Radiat Oncol Biol Phys. 1 août, vol.65, issue.5, pp.1536-1579, 2006. ,
, Targeting ?v?3 and ?v?5 integrins
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group, Neurooncology, vol.15, issue.10, pp.1438-1482, 2013. ,
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium, Invest New Drugs. avr, vol.30, issue.2, pp.749-57, 2012. ,
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer, vol.6, 2006. ,
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma, Melanoma Res. août, vol.22, issue.4, pp.294-301, 2012. ,
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer, Invest New Drugs. févr, vol.31, issue.1, pp.175-82, 2013. ,
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO), Ann Oncol. août, vol.26, issue.8, pp.1734-1774, 2015. ,
?1 integrin inhibition elicits a prometastatic switch through the TGF?-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer, Sci Signal. 11 févr, vol.7, issue.312, p.15, 2014. ,
Integrin ?(v)??-targeted radiotracer (99m)Tc-3P-RGD? useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin ?(v)?? RGD? therapy, Theranostics, vol.3, issue.11, pp.816-846, 2013. ,
Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery, Neurosurgery. août, vol.49, issue.2, pp.380-389, 2001. ,
Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature, Brain Pathol. juill, vol.18, issue.3, pp.378-86, 2008. ,
Longitudinal expression analysis of ?v integrins in human gliomas reveals upregulation of integrin ?v?3 as a negative prognostic factor, J Neuropathol Exp Neurol. mars, vol.72, issue.3, pp.194-210, 2013. ,
Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB, Int J Cancer. 15 juill, vol.123, issue.2, pp.357-64, 2008. ,
A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding, Integrins. Sci Rep, vol.11, p.39805, 2017. ,
Breaking the dogma of the metalcoordinating carboxylate group in integrin ligands: introducing hydroxamic acids to the MIDAS to tune potency and selectivity, Angew Chem Int Ed Engl, vol.48, issue.24, pp.4436-4476, 2009. ,
Conformational restrictions of biologically active peptides via amino acid side chain groups, Life Sciences. juill, vol.31, issue.3, pp.189-99, 1982. ,
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists, J Med Chem. 12 août, vol.42, issue.16, pp.3033-3073, 1999. ,
Increasing ?v?3 selectivity of the anti-angiogenic drug cilengitide by N-methylation, Angew Chem Int Ed Engl. 26 sept, vol.50, issue.40, pp.9496-500, 2011. ,
Pharmacophoric Modifications Lead to Superpotent ?v?3 Integrin Ligands with Suppressed ?5?1 Activity, Journal of Medicinal Chemistry. 24 avr, vol.57, issue.8, pp.3410-3417, 2014. ,
, Curr Opin Investig Drugs. juin, vol.4, issue.6, pp.741-746, 2003.
alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin, Int J Cancer. 10 avr, vol.98, issue.5, pp.690-697, 2002. ,
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro, Neuro-oncology. déc, vol.11, issue.6, pp.747-56, 2009. ,
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist, Neurosurgery. janv, vol.48, issue.1, pp.151-158, 2001. ,
Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice, Neurosurgery. déc, vol.59, issue.6, pp.1304-1316, 2006. ,
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency, Int J Cancer. 1 juin, vol.124, issue.11, pp.2719-2746, 2009. ,
AI-14 * THE ANTI ANGIOGENIC AND INVASIVE EFFECTS OF AN INTEGRIN INHIBITOR AGAINST BEVACIZUMAB-INDUCED INVASIVE GLIOMA, Neuro-Oncology, vol.16, issue.5, pp.4-4, 2014. ,
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma, J Clin Oncol. 1 mai, vol.25, issue.13, pp.1651-1658, 2007. ,
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma, Neuro-oncology, vol.17, issue.10, pp.1386-92, 2015. ,
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme, J Clin Oncol. 1 déc, vol.26, issue.34, pp.5610-5617, 2008. ,
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma, J Clin Oncol. 1 juin, vol.28, issue.16, pp.2712-2720, 2010. ,
Superactivation of integrin alphavbeta3 by low antagonist concentrations, J Cell Sci. avr, vol.114, pp.1545-53, 2001. ,
Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors, Nat Med. avr, vol.15, issue.4, pp.392-400, 2009. ,
Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread, Cancer Cell. 12 janv, vol.27, issue.1, pp.123-160, 2015. ,
Integrin ?V?3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair, Oncotarget. 25 avr, vol.8, issue.17, pp.27754-71, 2017. ,
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma, Cancer Cell. 11 déc, vol.32, issue.6, pp.856-868, 2017. ,
CD151-?3?1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion, Oncotarget, vol.6, issue.30, pp.29675-93, 2015. ,
?v?8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion, Mol Biol Cell. févr, vol.24, issue.4, pp.474-82, 2013. ,
Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by ?8 integrin, Cancer Res, vol.71, issue.20, pp.6371-81, 2011. ,
Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update, Oncotarget, vol.8, issue.49, pp.86947-68, 2017. ,
Ligand Binding Analysis for Human ?5?1 ,
Strategies for Designing New ?5?1 Integrin Antagonists, Journal of Medicinal Chemistry. juin, vol.48, issue.13, pp.4204-4211, 2005. ,
Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins, Cell, vol.95, issue.4, pp.507-526, 1998. ,
Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins, Nat Med. janv, vol.8, issue.1, pp.27-34, 2002. ,
Insights and questions arising from studies of a mouse model of Glanzmann thrombasthenia, Thromb Haemost. août, vol.82, issue.2, pp.481-486, 1999. ,
Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice, Cancer Res. 1 déc, vol.64, issue.23, pp.8643-50, 2004. ,
Redefining the role(s) of endothelial ?v?3-integrin in angiogenesis, Biochem Soc Trans. déc, vol.42, issue.6, pp.1590-1595, 2014. ,
Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies, Arterioscler Thromb Vasc Biol. 1 juin, vol.22, issue.6, pp.927-960, 2002. ,
Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin, Am J Pathol. avr, vol.156, issue.4, pp.1345-62, 2000. ,
Beta1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis, Dev Dyn. janv, vol.237, issue.1, pp.75-82, 2008. ,
Selective PET Imaging of Integrin Subtypes ?5?1 and ?v?3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin, Am J Pathol. juill, vol.57, issue.3, pp.193-211, 2005. ,
A public database for gene expression in human cancers, Cancer Res, vol.59, issue.21, pp.5403-5410, 1999. ,
Differentiation between high-and lowgrade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin, Am J Pathol, vol.161, issue.5, pp.1695-700, 2002. ,
Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice ,
URL : https://hal.archives-ouvertes.fr/hal-00862133
, Oncogene. 26 juin, vol.33, issue.26, pp.3451-62, 2014.
Design and Synthesis of a New Class of Selective Integrin ?5?1 Antagonists, Journal of Medicinal Chemistry. août, vol.50, issue.16, pp.3786-94, 2007. ,
Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice, Int J Cancer. 20 avr, vol.104, issue.4, pp.496-503, 2003. ,
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study, Clin Cancer Res. 1 déc, vol.14, issue.23, pp.7924-7933, 2008. ,
A phase II, single-arm study of the anti-?5?1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer, Gynecol Oncol. 1 mai, vol.121, issue.2, pp.273-282, 2011. ,
The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo, Invest Ophthalmol Vis Sci. 14 sept, vol.52, issue.10, pp.7213-7233, 2011. ,
Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth, Clin Cancer Res. 1 avr, vol.14, issue.7, pp.2137-2181, 2008. ,
A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo, Mol Cancer Ther. sept, vol.5, issue.9, pp.2271-80, 2006. ,
ATN-161 Peptide Functionalized Reversibly Cross-Linked Polymersomes Mediate Targeted Doxorubicin Delivery into Melanoma-Bearing C57BL/6 Mice, Molecular Pharmaceutics. 7 août, vol.14, issue.8, pp.2538-2585, 2017. ,
Probing Integrin Selectivity: Rational Design of Highly Active and Selective Ligands for the ?5?1 and ?v?3 Integrin Receptor, Angewandte Chemie International Edition. 4 mai, vol.46, pp.3571-3575, 2007. ,
Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor, Chembiochem. 16 juin, vol.9, issue.9, pp.1397-407, 2008. ,
Single cell tracking assay reveals an opposite effect of selective small non-peptidic ?5?1 or ?v?3/?5 integrin antagonists in U87MG glioma cells, Biochim Biophys Acta. sept, vol.1840, issue.9, pp.2978-87, 2014. ,
Glioma cell dispersion is driven by ?5 integrin-mediated cell-matrix and cell-cell interactions, Cancer Lett, vol.01, issue.2, pp.328-366, 2016. ,
alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells, Int J Cancer. 1 sept, vol.127, issue.5, pp.1240-1248, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00508230
Comparative studies of vertebrate Beta integrin genes and proteins: ancient genes in vertebrate evolution, Biomolecules, vol.23, 2011. ,
, High-throughput flow cytometry screening
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell. janv, vol.17, issue.1, pp.98-110, 2010. ,
Enumeration of neural stem and progenitor cells in the neural colony-forming cell assay, Stem Cells. avr, vol.26, issue.4, pp.988-96, 2008. ,
Integrin ?7: a major driver and therapeutic target for glioblastoma malignancy, Stem Cell Investig, vol.4, p.97, 2017. ,
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma, Genes & Development. 15 août, vol.24, issue.16, pp.1731-1776, 2010. ,
Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression, Cell Stem Cell. 5 avr, vol.22, issue.4, pp.514-528, 2018. ,
Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization, Oncogene. 4 mai, vol.25, pp.2818-2844, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00153723
Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images, NeuroOncology. 1 mai, vol.15, issue.5, pp.626-660, 2013. ,
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma, Am J Pathol. mai, vol.180, issue.5, pp.2108-2127, 2012. ,
Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses, J Neurooncol, vol.131, issue.1, pp.11-20, 2017. ,
Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis, Neuro-oncology, vol.19, issue.12, pp.1599-606, 2017. ,
Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids. BMC Cancer, vol.18, p.338, 2017. ,
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome, Oncotarget. 22 mars, vol.7, issue.12, pp.15018-15050, 2016. ,
Prognostic significance of ?5?1-integrin expression in cervical cancer, Asian Pac J Cancer Prev, vol.14, issue.6, pp.3891-3896, 2013. ,
The epidemiology of cervical cancer, Cancer J. oct, vol.9, issue.5, pp.348-59, 2003. ,
Advances in diagnosis and treatment of metastatic cervical cancer, J Gynecol Oncol. juill, vol.27, issue.4, p.43, 2016. ,
Cervical cancer metastasis to the brain: A case report and review of literature, Surgical Neurology International, vol.8, issue.1, p.181, 2017. ,
Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties, PLoS ONE, vol.7, issue.2, p.31864, 2012. ,
Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance, BMC Cancer. 28 janv, vol.12, p.48, 2012. ,
Enrichment and characterization of cancer stem-like cells from a cervical cancer cell line, Mol Med Rep. juin, vol.9, issue.6, pp.2117-2140, 2014. ,
Patient-derived xenograft models of squamous cell carcinoma of the uterine cervix, Cancer Lett. 10 avr, vol.373, issue.2, pp.147-55, 2016. ,
Cancer stem cells (CSCs), cervical CSCs and targeted therapies, Oncotarget. 23 mai, vol.8, issue.21, pp.35351-67, 2017. ,
Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins, J Cell Biochem, vol.102, issue.4, pp.829-868, 2007. ,
Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis, Semin Cancer Biol. 30 juin, 2018. ,
Glycosylation of Cancer Stem Cells: Function in Stemness, Tumorigenesis, and Metastasis, Neoplasia. août, vol.20, issue.8, pp.813-838, 2018. ,
TAT-mediated si-hWAPL inhibits the invasion and metastasis of cervical cancer stem cells, Exp Ther Med. déc, vol.14, issue.6, pp.5452-5460, 2017. ,
TGF-?1-induced CK17 enhances cancer stem cell-like properties rather than EMT in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway, FEBS J, vol.284, issue.18, pp.3000-3017, 2017. ,
Integrin ?5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway, Cancer Lett, vol.433, pp.199-209, 2018. ,
RUNX2 promotes breast cancer bone metastasis by increasing integrin ?5-mediated colonization, Cancer Lett, vol.28, issue.1, pp.78-86, 2016. ,
Involvement of ?5 integrin in survivin-mediated osteosarcoma metastasis ,
, Asian Pac J Trop Med. mai, vol.9, issue.5, pp.478-83, 2016.
Upregulation of microRNA-31 targeting integrin ?5 ,
TMPRSS4 regulates levels of integrin ?5 in NSCLC through miR-205 activity to promote metastasis, Br J Cancer. 4 févr, vol.110, issue.3, pp.764-74, 2014. ,
Expression and significance of the protein and mRNA of metastasis suppressor gene ME491/CD63 and integrin alpha5 in ovarian cancer tissues, Eur J Gynaecol Oncol, vol.28, issue.3, pp.179-83, 2007. ,
Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis, Mol Cancer. 13 juill, vol.10, p.84, 2011. ,
Notch signalling induces epithelial-mesenchymal transition to promote metastasis in oral squamous cell carcinoma, International Journal of Molecular Medicine, vol.12, issue.2018 ,
,
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target, Cancer Res. 1 avr, vol.68, issue.7, pp.2329-2368, 2008. ,
ZEB2 upregulates integrin ?5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells, Carcinogenesis. mars, vol.33, issue.3, pp.563-71, 2012. ,